Pioneering combination therapies may be the key to life saving cancer therapy

October 22, 2001

Blending old treatments and new ideas is transforming cancer care, ECCO 11 - the European Cancer Conference heard today (Monday 22 October) in Lisbon.

Scientists reported a number of studies involving combinations of radiotherapy and chemotherapy (drug therapy) in the treatment of common cancers. Cisplatin, a clear fluid administered as an infusion, featured in two of the presentations.

Radiotherapy was discovered nearly a 100 years ago. Cisplatin was discovered by accident in the mid-60s by scientists studying the effect of electric current on the E.Coli bacterium; and has been used to treat cervical, testicular, ovarian, bladder and small cell lung cancer.

Radical radiation therapy has been the accepted standard of care for advanced cervical cancer. But combining radiotherapy with cisplatin seems to achieve better results. Survival rates for combined treatment were 9 to 18 per cent higher in five phase III clinical trials.

Commenting on these results, Dr. Gillian Thomas, of the Sunnybrook Regional Cancer Center, Toronto, Canada, told the Lisbon meeting "Seldom do we seem to have so many results from several clinical trials pointing in the same direction."

The trials compared various doses and schedules of cisplatin and radiotherapy to radiotherapy alone, extended radiotherapy, or radiation and hydroxyurea, another anti-cancer drug.

But Dr. Thomas pointed out that the evidence in favour of concurrent chemotherapy and radiotherapy was not entirely clear-cut. Two large Canadian studies showed no detectable benefit: the results suggested that the optimal regimens of concurrent "chemo-radiation" were ill defined. Dr. Thomas also asked if cisplatin was the key, or if other combinations of chemotherapy and radiotherapy would achieve similar results.

A Dutch team reported success in using combination of intra-arterial cisplatin and radiotherapy in treating advanced, inoperable head and neck cancer. Dr. Coen Rasch, of the Netherlands Cancer Institute, reported that about 90 per cent of the 85 patients went into complete remission. A phase III trial comparing systemic and intra-arterial chemoradiation is ongoing, currently with 80 patients.

Combination success stories were not restricted to cisplatin. A US team demonstrated a 52 per cent improvement in relapse free survival among patients with gastric cancer who received post-operative combined radiotherapy and chemotherapy with Leucovorin. Dr. John Macdonald, of the Saint Vincent's Comprehensive Cancer Care Center, New York, reported a 32 per cent improvement in survival among patients in the combination arm of the study (median survival of 35 months compared with 26 months).
-end-
Abstracts No: Dr. Rasch, 33; Dr. Macdonald, 34; Dr. Thomas, 36.

For further information:
Maria Maneiro +351 21 892 1818 (until 25 October): +32 2 775 0203 (after 25 October)

ECCO-the European CanCer Organisation

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.